Surgical Castration in Hormone-Refractory Metastatic Prostate Cancer Patients Can Be an Alternative for Medical Castration
Table 1
Case No.
Age at orchiectomy
Prebiopsy PSA
Biopsy GS
LHRH agonist administered
Duration of LHRH agonist
PSA
Testosterone
Overall survival
pre-
post-
pre-
post-
1
75
69
8
goserelin
3.9
4.9
2.9
0.10
0.05>
14.9
2
80
488
9
leuprolide
2.5
3.3
2.1
0.12
0.05>
10.6
3
90
10.7
9
goserelin
13.8
29.6
14.9
0.14
0.05>
17.5<
4
76
4.7
8
goserelin
7.0
9.6
16.6
0.11
0.05>
13.7<
5
67
315
8
leuprolide
1.6
924
553
0.07
0.51
9.6
6
77
1463
9
leuprolide
2.1
696
914
0.05>
0.05>
10.1
7
78
2.8
7
leuprolide
1.0
12
4.2
0.05>
0.05>
9.7<
8
78
107
8
goserelin
1.7
0.26
0.12
0.05>
0.05>
3.3<
9*
77
200
7
goserelin
10.3
187
48
0.07
NA
10.1
10
80
426
9
goserelin
0.9
34.1
53.7
NA
0.22
14.8
11
69
334
8
leuprolide
3.2
7.0
0.8
NA
NA
26.1<
12
45
191
6
leuprolide
1.3
138
146
NA
NA
4.4
Units of PSA: ng/mL, GS: Gleason score, duration of LHRH agonist: years, units of serum testosterone: ng/mL, overall survival: survival after surgical castration (months), pre-: before surgical castration, post-: after surgical castration,
*: a case where decrease in PSA was supposed to be due to surgical castration.
